Personal Care Products

Marubi

Marubi released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 881.29 M (forecast CNY 881.29 M), actual EPS CNY 0.25 (forecast CNY 0.2519)

Marubi to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

Marubi released FY2025 Annual Earnings on March 31 Pre-Market (BJT), actual revenue CNY 3.459 B (forecast CNY 3.659 B), actual EPS CNY 0.62 (forecast CNY 0.9992)

Marubi released FY2025 Q4 earnings on March 31 Pre-Market (BJT), actual revenue CNY 1.009 B (forecast CNY 1.153 B), actual EPS CNY 0.0084 (forecast CNY 0.3613)

Marubi to release FY2025 earnings on April 1, pre-market (BJT), forecast revenue CNY 3.659 B, EPS CNY 0.9706

Marubi released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 681.19 M (forecast CNY 779.38 M), actual EPS CNY 0.1483 (forecast CNY 0.1577)

Marubi released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 2.45 B, actual EPS CNY 0.6119

Marubi to Release FY2025 Q3 Earnings on October 31 After-Market (BJT), Forecast Revenue CNY 779.38 M, EPS CNY 0.1577

Marubi released FY2025 Semi-Annual Earnings on August 22 During-Market (BJT), actual revenue CNY 1.769 B, actual EPS CNY 0.46

Marubi released FY2025 Q2 earnings on August 22 During-Market (BJT), actual revenue CNY 922.54 M (forecast CNY 954.22 M), actual EPS CNY 0.1235 (forecast CNY 0.283)

Marubi FY2025 Semi-Annual Earnings Release on August 23, 2025 (BJT)

Plants Doctor Plans Shenzhen Stock Exchange Listing, Revenue Growth Slows

Guangdong Wamai Continues to Increase Trademark Registration Applications

Wanmei Bio Secretary Comments on 618 Sales and Investment Projects

ECM Materials in Regenerative Medicine Experience a Development Turning Point

MaryKay Biologics Reports Q1 2025 Revenue Growth

Wanmei Biotechnology Company Fully Owned by Wanmei Biotech

ManeBio Received Buy Ratings from Multiple Securities Firms

Opening Securities Issues Buy Rating Report on Wanmei Bio

A-share beauty and healthcare sector surges in afternoon trading

603983

Marubi announced that its revenue for the third quarter was 686 million yuan, a year-on-year increase of 14.28%; net profit was 69.4816 million yuan, a year-on-year increase of 11.59%. Revenue for the first three quarters was 2.45 billion yuan, a year-on-year increase of 25.51%; net profit was 244 million yuan, a year-on-year increase of 2.13%

Zhitong

Marubi: The net profit for the third quarter was 69.4816 million yuan, a year-on-year increase of 11.59%

Marubi fell 6.76% today, with a transaction amount of 411 million yuan and a turnover rate of 2.44%. According to the after-hours dragon and tiger list data, the Shanghai Stock Connect dedicated seat bought 14.5546 million yuan and sold 12.6801 million yuan. One institutional dedicated seat had a net purchase of 5.8066 million yuan, while four institutional dedicated seats had a net sale of 117 million yuan

Marubi fell 6.76% today, with 4 institutional special seats net selling 117 million yuan

Huaxi Securities maintains a "Buy" rating on Marubi, expecting a net profit attributable to the parent company of 186 million yuan in H1 2025, a year-on-year increase of 5.21%. The net profit attributable to the parent company in Q2 2025 is expected to be 51 million yuan, a year-on-year decrease of 23.08%. The company plans to distribute a cash dividend of 2.5 yuan per share, with a dividend payout ratio of 53.97%. Marubi is developing synergistically with the PL Lianhuo brand, steadily increasing market penetration. The Shanghai Moyang Biotechnology Co., Ltd. invested in 2025 has obtained a Class III medical device registration certificate, demonstrating forward-looking layout. The brand focuses on a big product strategy, with classic products performing exceptionally well

West China Securities: Maintains "Buy" rating on Marubi, brand focuses on the big product strategy and continues to strengthen efforts

Marubi announced that in the first half of 2025, operating revenue reached 1.769 billion yuan, a year-on-year increase of 30.83%. Net profit was 186 million yuan, a year-on-year increase of 5.21%. Based on the total share capital registered on the equity distribution record date, a cash dividend of 2.5 yuan will be distributed for every 10 shares to all shareholders registered on the equity distribution record date

Marubi: Net profit of 186 million yuan in the first half of 2025, a year-on-year increase of 5.21%

600737

As Asian markets fluctuate, investors are identifying undervalued stocks. Notable mentions include SRE Holdings, SILICON2, and Nanya Technology, with estimated discounts of 48.7% to 49.5%. Cofco Sugar Holding and Guangdong Marubi Biotechnology also show significant undervaluation, with discounts of 40.3% and 48.7%, respectively. Both companies are expected to experience robust earnings growth, although concerns about dividend sustainability exist. The analysis suggests potential investment opportunities in these undervalued stocks based on cash flow assessments.

Simplywall

Cofco Sugar

3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 48.7%

603630

603238

603059

300740

The beauty and personal care sector has undergone significant adjustments, with Perfect hitting the daily limit down, and companies such as Bawei Co., SYG, Marubi, Lafang, and NBOND also experiencing declines

Lafang

NBOND

Perfect

The beauty and personal care sector has undergone significant adjustments, with Perfect hitting the daily limit down

301371

600223

300886

The cosmetics sector continues to decline, with Hyea Aromas falling over 6%, and Lafang, Fuerjia, Freda, Marubi, and others following suit

Fuerjia

Freda

Hyea Aromas

The cosmetics sector continues to decline, with Hyea Aromas falling over 6%

300132

603605

The cosmetics sector saw a short-term surge, with SYG rising over 10%. Marubi, Proya, Fulejia, Green Pine, and Babi also followed suit

Green Pine

Proya

The cosmetics sector has seen a short-term surge, with SYG rising over 10%

According to the Qichacha APP, recently, Marubi Biotechnology Co., Ltd. was established with a registered capital of 10 million yuan. The business scope includes: sales of personal hygiene products; sales of Class I medical devices; sales of Class II medical devices; medical research and experimental development, etc. Qichacha's equity penetration shows that the company is wholly owned by Marubi Biotechnology

Marubi established a subsidiary that includes medical research and experimental development business

300955

The cosmetics sector has seen a short-term decline, with JAHEN, Marubi, Lafang, Green Pine, and Huaye Fragrance all experiencing a drop

JAHEN

The cosmetics sector has seen a short-term decline

Marubi(603983.SH)